{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:13:05Z","timestamp":1778929985729,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP17K09595"],"award-info":[{"award-number":["JP17K09595"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16K08676"],"award-info":[{"award-number":["JP16K08676"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K16621"],"award-info":[{"award-number":["JP19K16621"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.athplu.2025.01.002","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T12:34:15Z","timestamp":1738326855000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and efficacy of edoxaban monotherapy after bioabsorbable polymer everolimus-eluting stent implantation in a human-like coronary atherosclerotic porcine model"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1791-8398","authenticated-orcid":false,"given":"Daisuke","family":"Kitano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Migita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Shimodai-Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiichiro","family":"Fuchimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.athplu.2025.01.002_bib1","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2025.01.002_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2025.01.002_bib3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","article-title":"JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease","volume":"84","author":"Nakamura","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.athplu.2025.01.002_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","article-title":"Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes","volume":"15","author":"Laudani","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.athplu.2025.01.002_bib5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"WOEST study investigators, Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2025.01.002_bib6","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2025.01.002_bib7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2025.01.002_bib8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2025.01.002_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2025.01.002_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2025.01.002_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002779","article-title":"Development of human-like advanced coronary plaques in low-density lipoprotein receptor knockout pigs and justification for statin treatment before formation of atherosclerotic plaques","volume":"5","author":"Li","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.athplu.2025.01.002_bib12","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1038\/s41598-021-85740-2","article-title":"Pathological findings after third- and second-generation everolimus-eluting stent implantations in coronary arteries from autopsy cases and an atherosclerotic porcine model","volume":"11","author":"Migita","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.athplu.2025.01.002_bib13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0091270010370974","article-title":"Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers","volume":"51","author":"Mendell","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.athplu.2025.01.002_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5551\/jat.56549","article-title":"Effect of rivaroxaban and clopidogrel combination therapy on in-stent responses after everolimus-eluting stent implantation in a porcine coronary model","volume":"29","author":"Kitano","year":"2022","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.athplu.2025.01.002_bib15","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jacc.2011.09.079","volume":"59","author":"Tearney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2025.01.002_bib16","first-page":"128","article-title":"Intravascular optical coherence tomography: optimisation of image acquisition and quantitative assessment of stent strut apposition","volume":"3","author":"Tanigawa","year":"2007","journal-title":"EuroIntervention"},{"key":"10.1016\/j.athplu.2025.01.002_bib17","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0735-1097(01)01175-5","volume":"37","author":"Mintz","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2025.01.002_bib18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.athplu.2025.01.002_bib19","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1161\/ATVBAHA.113.301227","article-title":"Tissue characterization after drug-eluting stent implantation using optical coherence tomography","volume":"33","author":"Malle","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2025.01.002_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000494059","article-title":"Prevention of stent thrombosis in rats by a direct oral factor Xa inhibitor edoxaban","volume":"103","author":"Morishima","year":"2019","journal-title":"Pharmacology"},{"key":"10.1016\/j.athplu.2025.01.002_bib21","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.3390\/jcm12237487","article-title":"Effectiveness of early direct oral anticoagulant monotherapy within one year of coronary stent implantation in patients with atrial fibrillation: a nationwide population-based study","volume":"12","author":"Hwang","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.athplu.2025.01.002_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5905022","article-title":"Edoxaban monotherapy in nonvalvular atrial fibrillation patients with coronary artery disease","volume":"2022","author":"Fukamachi","year":"2022","journal-title":"J Intervent Cardiol"},{"key":"10.1016\/j.athplu.2025.01.002_bib23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"OAC-ALONE study investigators, open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 Year after coronary stent implantation","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2025.01.002_bib24","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2025.01.002_bib25","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1161\/01.CIR.0000163587.36485.A7","article-title":"Molecular basis of restenosis and drug-eluting stents","volume":"111","author":"Costa","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2025.01.002_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood-2016-09-692996","article-title":"Emerging anticoagulant strategies","volume":"129","author":"Fredenburgh","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.athplu.2025.01.002_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0950-3536(05)80092-7","article-title":"Endothelial cell function and thrombosis","volume":"7","author":"Pearson","year":"1994","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.athplu.2025.01.002_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2016.02.028","article-title":"Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux","volume":"141","author":"Honda","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.athplu.2025.01.002_bib29","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1111\/jth.12033","article-title":"Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis","volume":"10","author":"Becker","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.athplu.2025.01.002_bib30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0735-1097(99)00596-3","article-title":"Platelets and restenosis","volume":"35","author":"Chandrasekar","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2025.01.002_bib31","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.ehj.2004.06.011","article-title":"Inflammation and restenosis after percutaneous coronary interventions","volume":"25","author":"Toutouzas","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2025.01.002_bib32","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1073\/pnas.89.6.2317","article-title":"Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells","volume":"89","author":"Gasic","year":"1992","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.athplu.2025.01.002_bib33","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI118938","article-title":"Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat","volume":"98","author":"Ko","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.athplu.2025.01.002_bib34","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1006\/bbrc.1997.7847","article-title":"Induction of vascular smooth muscle cell growth by selective activation of the proteinase activated receptor-2 (PAR-2)","volume":"241","author":"Bono","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.athplu.2025.01.002_bib35","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1172\/JCI1833","article-title":"Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo","volume":"101","author":"Herbert","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.athplu.2025.01.002_bib36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0014-5793(02)02948-4","article-title":"Factor Xa induces mitogenesis of coronary artery smooth muscle cell via activation of PAR-2","volume":"523","author":"Koo","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.athplu.2025.01.002_bib37","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1161\/01.CIR.89.3.1262","article-title":"Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits","volume":"89","author":"Ragosta","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2025.01.002_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2007.09.043","article-title":"PAR-2 mediates increased inflammatory cell adhesion and neointima formation following vascular injury in the mouse","volume":"198","author":"Tennant","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2025.01.002_bib39","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1161\/ATVBAHA.111.238261","article-title":"Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia","volume":"31","author":"Sevigny","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2025.01.002_bib40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0049-3848(99)00213-3","article-title":"A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats","volume":"98","author":"Kaiser","year":"2000","journal-title":"Thromb Res"},{"key":"10.1016\/j.athplu.2025.01.002_bib41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11239-018-1673-7","article-title":"A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice","volume":"46","author":"Morishima","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.athplu.2025.01.002_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2020.106661","article-title":"Effects of edoxaban and warfarin on vascular remodeling: atherosclerotic plaque progression and collateral artery growth","volume":"127","author":"Millenaar","year":"2020","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.athplu.2025.01.002_bib43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejphar.2017.12.037","article-title":"Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury","volume":"820","author":"Hara","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.athplu.2025.01.002_bib44","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jacbts.2021.09.010","article-title":"Rivaroxaban, a direct oral factor Xa inhibitor, attenuates atherosclerosis by alleviating factor xa\u2013PAR2-mediated autophagy suppression","volume":"6","author":"Ito","year":"2021","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.athplu.2025.01.002_bib45","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1080\/14656566.2021.1937119","article-title":"An update on antithrombotic therapy in atrial fibrillation patients in long-term ambulatory setting after percutaneous coronary intervention: where do we go from here?","volume":"22","author":"Marazzato","year":"2021","journal-title":"Expert Opin. Pharmacother."}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089525000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089525000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:02:14Z","timestamp":1778929334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667089525000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":45,"alternative-id":["S2667089525000021"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2025.01.002","relation":{},"ISSN":["2667-0895"],"issn-type":[{"value":"2667-0895","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of edoxaban monotherapy after bioabsorbable polymer everolimus-eluting stent implantation in a human-like coronary atherosclerotic porcine model","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2025.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}